Salt Sensitivity of Blood PressureNCT04258332

CARDIA-Salt Sensitivity of Blood Pressure (SSBP)

A study testing High Salt Diet and Low Salt Diet in people with Salt Sensitivity of Blood Pressure and Hypertension, run by Vanderbilt University Medical Center at 2 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

Who is it for?: Ages 50 to 70 yearsHealthy volunteers can take part
Conditions the study is for: Salt Sensitivity of Blood Pressure, Hypertension
What is being tested?: High Salt Diet and Low Salt Diet
Type of treatment: Pill or oral medicine
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 281 participants
Where: 2 sitesUnited States
Study dates: 17 May 2021to 17 May 2025
Phase: Interventional
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 50 to 70 years
All sexes
Healthy volunteers accepted
Adult, Older adult

Who may be able to join

Potentially eligible individuals must consent to and be willing to adhere to the study protocol. We will include individuals not taking anti-HTN medications, i.e. normotensives and untreated hypertensives, and individuals with controlled HTN by use of ≤ 3 anti-HTN medications.

Who cannot join

Unwilling to adhere to the study protocol
Resistant HTN, defined as taking ≥ 4 anti-HTN medications to control BP or uncontrolled BP despite ≥ 3 anti-HTN medications that includes a diuretic
Contraindications to high- or low-salt diet (e.g. heart, renal, or liver failure, postural orthostatic tachycardia syndrome)
Use of salt tabs, fludricortisone, midodrine
Contraindications to 24hr ABPM: bilateral upper extremity lymphedema, cuff will not fit
Medical contraindications to foods, e.g. celiac disease, nut allergy, egg allergy, etc.

Show all 10Show fewer

Year 35 core exam systolic BP < 90 or > 160 mm Hg or diastolic BP < 50 or > 100 mm Hg
Current use of steroids, NSAIDS, anti-inflammatories
Rheumatologic condition (e.g. Lupus, Rheumatoid Arthritis, Psoriatic arthritis, Inflammatory Bowel Disease, Multiple Sclerosis
Immune deficiency or immunosuppressed

Trial locations and contacts

2 sites in 1 country.

United States2 sites

University of Alabama Birmingham
Birmingham, Alabama, 35294
Northwestern University
Chicago, Illinois, 60611

Other trials in United States

About this study

Official title: Dietary Sodium Inflammation and Salt Sensitivity of Blood Pressure

Salt sensitivity of blood pressure (SSBP) is defined as the change in blood pressure (BP) in relation to change in salt intake. An increase in BP from low- to high-salt diet is common and associated with an increased risk of cardiovascular morbidity and mortality, even among normotensive individuals. Yet, the pathophysiology of SSBP is not well understood. The prevailing paradigm is that abnormalities of neurohormones that regulate sodium (Na+) retention and excretion and/or Na+ transporting pathways create Na+ imbalances that underlie susceptibility to SSBP. As a homeostatic mechanism, BP fluctuates to maintain Na+ balance, i.e. higher BP is needed for pressure natriuresis to excrete excess Na+. An alternate framework emphasizes vascular dysregulation as the inciting mechanism. In both constructs, how Na+ itself influences BP remains incompletely understood. Our preliminary work suggests that excess Na+ induces a pro-inflammatory state that sustains higher BP. Interleukin-6 (IL-6) drives the induction of interleukin-17 (IL-17) secreting T helper 17 cells that were recently demonstrated to be pathogenic in response to Na+ exposure. IL-6, IL-17 and related cytokines regulate renal Na+ transporters and raise BP through vascular inflammation, fibrosis, and impaired vasodilation. The immune response to high- and low-salt diet in humans, however, is not completely understood, emphasizing the need for more detailed human studies, with deeper immune profiling under controlled salt conditions and with neurohormonal assessment. Our overarching postulate is that the inflammatory response to excess dietary salt intake is associated with SSBP. The Coronary Artery Risk Development in Young Adults (CARDIA) study is the ideal cohort in which to translate our preliminary findings. Investigators propose to investigate SSBP in CARDIA using standardized low- and high-salt diets and 24-hour ambulatory BP monitoring. Investigators will quantify SSBP in a total of 500 participants from the Chicago and Birmingham field centers during the upcoming year 35 exam (beginning in 2020). Our specific aims are: 1) to define the distribution of SSBP and its clinical correlates in a contemporary community-based US cohort of middle-aged individuals; 2) to investigate the immune response to dietary salt loading, and 3) to investigate the association between the immune and BP responses to dietary salt loading. The proposed study represents a unique opportunity to leverage a large, well-phenotyped cohort to test novel hypotheses regarding SSBP. Phenotyping SSBP using standardized high- and low-salt diets in CARDIA will be novel as this has never been performed in any of the existing US based NHLBI sponsored cardiovascular epidemiologic cohorts. The proposed work has the potential to yield a more readily available approach for differentiating an individual as salt-sensitive or resistant. New insights into the pathophysiology of SSBP should also provide a foundation for investigating high-impact clinical applications, by informing future studies of therapies directed at SSBP. The scientific rigor is further enhanced by the rich clinical, genetic, and biochemical data available in CARDIA.

Conditions: Salt Sensitivity of Blood Pressure, Hypertension
Being tested: High Salt Diet, Low Salt Diet
Medical subject headings: Hypertension

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

High Salt DietDietary supplement
Patients will be randomized to be on a high salt diet for 7 days.
Low Salt DietDietary supplement
Patients will be randomized to be on a low salt for 7 days.

Study groups in NCT04258332
Study group	Role	What they receive
High Salt Diet then Low Salt Diet	Other	The high-salt diet will be achieved through the supplementation of each participant's usual diet with Na+ bullion packets (2 packets per day). This will increase Na+ intake by approximately 2,200 mg (≈100 mEq Na+) to a total greater than 5,000 mg Na+ per day based on prior estimates of Na+ intake (see section C1.2). In addition, 1,000 mg of calcium carbonate (provided via Tums tablets) will be taken daily on the high Na+ diet to reduce the potential impact of changes in calcium intake on blood pressure. The low-salt diet is comprised of 7 days of freshly prepared frozen meals, snacks, and Na+ free water. All low-salt meals will be prepared in each site's Metabolic Kitchen, with standardization of diets across sites. The low-salt diet includes: 20 mEq Na+ (±2 mEq) (460 mg/day), 100 mEq potassium (±2 mEq), and 1,000 mg calcium (±50 mg). Receives: Dietary Supplement: High Salt Diet; Dietary Supplement: Low Salt Diet
Low Salt Diet then High Salt Diet	Other	The low-salt diet is comprised of 7 days of freshly prepared frozen meals, snacks, and Na+ free water. All low-salt meals will be prepared in each site's Metabolic Kitchen, with standardization of diets across sites. The low-salt diet includes: 20 mEq Na+ (±2 mEq) (460 mg/day), 100 mEq potassium (±2 mEq), and 1,000 mg calcium (±50 mg). The high-salt diet will be achieved through the supplementation of each participant's usual diet with Na+ bullion packets (2 packets per day). This will increase Na+ intake by approximately 2,200 mg (≈100 mEq Na+) to a total greater than 5,000 mg Na+ per day based on prior estimates of Na+ intake (see section C1.2). In addition, 1,000 mg of calcium carbonate (provided via Tums tablets) will be taken daily on the high Na+ diet to reduce the potential impact of changes in calcium intake on blood pressure. Receives: Dietary Supplement: High Salt Diet; Dietary Supplement: Low Salt Diet

What is being measured

The primary outcome is the main question the study is designed to answer.

Salt Sensitivity of Blood Pressure
The change in 24-hour ambulatory mean arterial pressure (MAP) following one week of high-salt and following one week of low-salt diet. This is calculated as the 24 hour ambulatory MAP on the high-salt diet minus the 24 hour ambulatory MAP on the low-salt diet.
Measured: 14 days total which is 7 days each of high- and low-salt diet
Immune Response to Dietary Salt Loading, Change in Circulating Levels of IL-6
The change in circulating levels of interleukin-6 (IL-6) following one week of high-salt and following one week of low-salt diet. This is calculated as the IL-6 level on the high-salt diet minus the IL-6 level on the low-salt diet.
Measured: 14 days total which is 7 days each of high- and low-salt diet
Immune Response to Dietary Salt Loading, Change in Circulating Levels of IL-17
The change in circulating levels of interleukin-17 (IL-17) following one week of high-salt and following one week of low-salt diet. This is calculated as the IL-17 level on the high-salt diet minus the IL-17 level on the low-salt diet.
Measured: 14 days total which is 7 days each of high- and low-salt diet
Immune Response to Dietary Salt Loading, IL-10, Change in Circulating Levels of IL-10
The change in circulating levels of interleukin-10 (IL-10) following one week of high-salt and following one week of low-salt diet. This is calculated as the IL-10 level on the high-salt diet minus the IL-10 level on the low-salt diet.
Measured: 14 days total which is 7 days each of high- and low-salt diet

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

17 May 202117 May 2025

First posted6 Feb 2020
Study start17 May 2021
Primary completion17 May 2025
Study completion17 May 2025

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Publications (1)Papers the sponsor has linked to this study.
Other trials for Salt Sensitivity of Blood PressureStudies of the same condition, open and under way.
More trials run by Vanderbilt University Medical CenterThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Other
Allocation: Randomised
Intervention model: Crossover
Masking: None (open label)
Enrolment: 281 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT04258332
Sponsor's protocol ID: 190622
Status last verified: Jun 2026
First submitted: 4 Feb 2020
Last updated: 7 Jul 2026
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: Yes: Research data will be shared according to the most recent NIH guideline. The data collected will be made available by the CARDIA Data Coordinating Center (DCC) both to the study for use by other investigators and to NHLBI for inclusion in the NHLBI's Data Repository Program, in accordance with the NHLBI Policy for Data Sharing from Clinical Trials and Epidemiological Studies, http://www.nhlbi.nih.gov/funding/datasharing.htm. Through the conduct of the study and in resource sharing, attention will be given to protect private health information; thus, we will make data available to others through the CARDIA DCC under a data use agreement specifying (1) to use the data only for research purposes and not to identify an individual participant; (2) to secure the data using appropriate computer technology; and (3) to destroy or return the data after analyses are completed. The overall CARDIA DCC at the UAB will be responsible for overseeing approval and sharing of research data.

Publications

Gupta DK, Lewis CE, Varady KA, Su YR, Madhur MS, Lackland DT, Reis JP, Wang TJ, Lloyd-Jones DM, Allen NB. Effect of Dietary Sodium on Blood Pressure: A Crossover Trial. JAMA. 2023 Dec 19;330(23):2258-2266. doi: 10.1001/jama.2023.23651.
PubMed 37950918

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

RecruitingPhase 2
Effect of an Isolevuglandin Scavenger on Salt Sensitivity of Blood Pressure and Immune Cell Activation in Humans
Salt Sensitivity of Blood Pressure, High Blood Pressure
Not yet recruiting
Beta-2 Adrenergic Receptor Polymorphic Variants: An Endotype of Salt Sensitive Hypertension (Beta2AR).
Genetics in Hypertension
Not yet recruiting
Gut Microbiome, Metabolome, and SSBP
Salt-sensitivity of Blood Pressure
Recruiting
Salt Sensitivity Evaluation Via N-of-1 Trials (SENSE-Salt)
Salt-Sensitivity of Blood Pressure, Hypertension
RecruitingPhase 4
Forebrain Electroneutral Transporters in Salt-sensitive Hypertension: an MRI Study
Salt-Sensitivity of Blood Pressure

All Salt Sensitivity of Blood Pressure trials

Study at a glance

From the registry record, last updated by the sponsor on 7 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Dietary Sodium Inflammation and Salt Sensitivity of Blood Pressure
ClinicalTrials.gov ID: NCT04258332
Acronym / sponsor ID: 190622
Conditions: Salt Sensitivity of Blood Pressure, Hypertension
Study type: Interventional
Recruitment status: Completed
Enrolment: 281 participants (actual)
Lead sponsor: Vanderbilt University Medical CenterUniversity, hospital or other
Collaborators: Northwestern University, University of Alabama at Birmingham
Study start: 17 May 2021 (actual)
Primary completion: 17 May 2025 (actual)
Study completion: 17 May 2025 (actual)
First posted: 6 Feb 2020 (actual)
Results: Posted 7 Jul 2026

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Primary purpose: Other
Allocation: Randomised
Intervention model: Crossover
Masking: None (open label)
Number of arms: 2

Arm	Type	Receives
High Salt Diet then Low Salt Diet	Other	Dietary Supplement: High Salt Diet, Dietary Supplement: Low Salt DietThe high-salt diet will be achieved through the supplementation of each participant's usual diet with Na+ bullion packets (2 packets per day). This will increase Na+ intake by approximately 2,200 mg (≈100 mEq Na+) to a total greater than 5,000 mg Na+ per day based on prior estimates of Na+ intake (see section C1.2). In addition, 1,000 mg of calcium carbonate (provided via Tums tablets) will be taken daily on the high Na+ diet to reduce the potential impact of changes in calcium intake on blood pressure. The low-salt diet is comprised of 7 days of freshly prepared frozen meals, snacks, and Na+ free water. All low-salt meals will be prepared in each site's Metabolic Kitchen, with standardization of diets across sites. The low-salt diet includes: 20 mEq Na+ (±2 mEq) (460 mg/day), 100 mEq potassium (±2 mEq), and 1,000 mg calcium (±50 mg).
Low Salt Diet then High Salt Diet	Other	Dietary Supplement: High Salt Diet, Dietary Supplement: Low Salt DietThe low-salt diet is comprised of 7 days of freshly prepared frozen meals, snacks, and Na+ free water. All low-salt meals will be prepared in each site's Metabolic Kitchen, with standardization of diets across sites. The low-salt diet includes: 20 mEq Na+ (±2 mEq) (460 mg/day), 100 mEq potassium (±2 mEq), and 1,000 mg calcium (±50 mg). The high-salt diet will be achieved through the supplementation of each participant's usual diet with Na+ bullion packets (2 packets per day). This will increase Na+ intake by approximately 2,200 mg (≈100 mEq Na+) to a total greater than 5,000 mg Na+ per day based on prior estimates of Na+ intake (see section C1.2). In addition, 1,000 mg of calcium carbonate (provided via Tums tablets) will be taken daily on the high Na+ diet to reduce the potential impact of changes in calcium intake on blood pressure.

Who may qualify

Ages: 50 to 70 years
Sex: All
Healthy volunteers: Accepted
Age groups: Adult, Older adult

Key inclusion criteria (1 listed)

Potentially eligible individuals must consent to and be willing to adhere to the study protocol. We will include individuals not taking anti-HTN medications, i.e. normotensives and untreated hypertensives, and individuals with controlled HTN by use of ≤ 3 anti-HTN medications.

Key exclusion criteria (10 listed)

Unwilling to adhere to the study protocol
Resistant HTN, defined as taking ≥ 4 anti-HTN medications to control BP or uncontrolled BP despite ≥ 3 anti-HTN medications that includes a diuretic
Contraindications to high- or low-salt diet (e.g. heart, renal, or liver failure, postural orthostatic tachycardia syndrome)
Use of salt tabs, fludricortisone, midodrine
Contraindications to 24hr ABPM: bilateral upper extremity lymphedema, cuff will not fit

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
High Salt DietPatients will be randomized to be on a high salt diet for 7 days.	Dietary supplement	High Salt Diet then Low Salt Diet, Low Salt Diet then High Salt Diet
Low Salt DietPatients will be randomized to be on a low salt for 7 days.	Dietary supplement	High Salt Diet then Low Salt Diet, Low Salt Diet then High Salt Diet

Primary outcome

Salt Sensitivity of Blood Pressure
Time frame: 14 days total which is 7 days each of high- and low-salt diet
The change in 24-hour ambulatory mean arterial pressure (MAP) following one week of high-salt and following one week of low-salt diet. This is calculated as the 24 hour ambulatory MAP on the high-salt diet minus the 24 hour ambulatory MAP on the low-salt diet.
Immune Response to Dietary Salt Loading, Change in Circulating Levels of IL-6
Time frame: 14 days total which is 7 days each of high- and low-salt diet
The change in circulating levels of interleukin-6 (IL-6) following one week of high-salt and following one week of low-salt diet. This is calculated as the IL-6 level on the high-salt diet minus the IL-6 level on the low-salt diet.
Immune Response to Dietary Salt Loading, Change in Circulating Levels of IL-17
Time frame: 14 days total which is 7 days each of high- and low-salt diet
The change in circulating levels of interleukin-17 (IL-17) following one week of high-salt and following one week of low-salt diet. This is calculated as the IL-17 level on the high-salt diet minus the IL-17 level on the low-salt diet.
Immune Response to Dietary Salt Loading, IL-10, Change in Circulating Levels of IL-10
Time frame: 14 days total which is 7 days each of high- and low-salt diet
The change in circulating levels of interleukin-10 (IL-10) following one week of high-salt and following one week of low-salt diet. This is calculated as the IL-10 level on the high-salt diet minus the IL-10 level on the low-salt diet.

Results and safety

Results posted to the registry on 7 Jul 2026, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
High Salt Diet Then Low Salt Diet	124	118
Low Salt Diet Then High Salt Diet	104	95

Primary outcome: Salt Sensitivity of Blood Pressure

Time frame: 14 days total which is 7 days each of high- and low-salt diet. Median (Inter-Quartile Range). Unit: mm Hg

Measure	High Salt Diet Then Low Salt Diet n = 118	Low Salt Diet Then High Salt Diet n = 95
Value	4.0 (0.3 to 7.0)	3.2 (-1.2 to 8.8)

Population analysed: Participants were randomized to one of two arms: either a high salt diet first, then low salt diet, or low salt diet first then low salt diet. The goal of the study was to quantify the within individual change in mean arterial pressure between high- and low-sodium diet. Therefore, arms are presented according to randomized diet order rather than overall high- or low-sodium diet at any point. In total it took 14 days to complete the high- and low-sodium diets that lasted for one-week each.

Primary outcome: Immune Response to Dietary Salt Loading, Change in Circulating Levels of IL-6

Time frame: 14 days total which is 7 days each of high- and low-salt diet. Median (Inter-Quartile Range). Unit: pg/ml

Measure	High Salt Diet Then Low Salt Diet n = 106	Low Salt Diet Then High Salt Diet n = 85
Value	-0.004 (-0.550 to 0.586)	-0.015 (-0.521 to 0.439)

Population analysed: Participants were randomized to one of two arms: either a high salt diet first, then low salt diet, or low salt diet first then low salt diet. The goal of this aim was to quantify the within individual change in interleukin-6 between high- and low-sodium diet. Therefore, arms are presented according to randomized diet order rather than overall high- or low-sodium diet at any point. In total it took 14 days to complete the high- and low-sodium diets that lasted for one-week each.

Primary outcome: Immune Response to Dietary Salt Loading, Change in Circulating Levels of IL-17

Time frame: 14 days total which is 7 days each of high- and low-salt diet. Median (Inter-Quartile Range). Unit: pg/ml

Measure	High Salt Diet Then Low Salt Diet n = 106	Low Salt Diet Then High Salt Diet n = 84
Value	0 (-0.98 to 1.05)	0 (-1.21 to 1.07)

Population analysed: Participants were randomized to one of two arms: either a high salt diet first, then low salt diet, or low salt diet first then low salt diet. The goal of this aim was to quantify the within individual change in interleukin-17 between high- and low-sodium diet. Therefore, arms are presented according to randomized diet order rather than overall high- or low-sodium diet at any point. In total it took 14 days to complete the high- and low-sodium diets that lasted for one-week each.

Primary outcome: Immune Response to Dietary Salt Loading, IL-10, Change in Circulating Levels of IL-10

Time frame: 14 days total which is 7 days each of high- and low-salt diet. Median (Inter-Quartile Range). Unit: pg/ml

Measure	High Salt Diet Then Low Salt Diet n = 106	Low Salt Diet Then High Salt Diet n = 84
Value	-0.17 (-0.72 to 0.74)	0.05 (-0.58 to 0.62)

Population analysed: Participants were randomized to one of two arms: either a high salt diet first, then low salt diet, or low salt diet first then low salt diet. The goal of this aim was to quantify the within individual change in interleukin-10 between high- and low-sodium diet. Therefore, arms are presented according to randomized diet order rather than overall high- or low-sodium diet at any point. In total it took 14 days to complete the high- and low-sodium diets that lasted for one-week each.

Adverse events

Time frame: 7 days during high-salt diet week and 7 days during low-salt diet week. Other adverse events reported at 0% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
High Salt Diet	0 of 217 (0%)	21 of 217 (9.7%)	0 of 217
Low Salt Diet	0 of 215 (0%)	17 of 215 (7.9%)	0 of 215

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 7 Jul 2026.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Derived from this study: PubMed 37950918Gupta DK, Lewis CE, Varady KA, Su YR, Madhur MS, Lackland DT, Reis JP, Wang TJ, Lloyd-Jones DM, Allen NB. Effect of Dietary Sodium on Blood Pressure: A Crossover Trial. JAMA. 2023 Dec 19;330(23):2258-2266. doi: 10.1001/jama.2023.23651.
Individual participant dataSharing planned: Yes. Research data will be shared according to the most recent NIH guideline. The data collected will be made available by the CARDIA Data Coordinating Center (DCC) both to the study for use by other investigators and to NHLBI for inclusion in the NHLBI's Data Repository Program, in accordance with the NHLBI Policy for Data Sharing from Clinical Trials and Epidemiological Studies, http://www.nhlbi.nih.gov/funding/datasharing.htm. Through the conduct of the study and in resource sharing, attention will be given to protect private health information; thus, we will make data available to others through the CARDIA DCC under a data use agreement specifying (1) to use the data only for research purposes and not to identify an individual participant; (2) to secure the data using appropriate computer technology; and (3) to destroy or return the data after analyses are completed. The overall CARDIA DCC at the UAB will be responsible for overseeing approval and sharing of research data.

Related trials for Salt Sensitivity of Blood Pressure

RecruitingPhase 2
Effect of an Isolevuglandin Scavenger on Salt Sensitivity of Blood Pressure and Immune Cell Activation in Humans
Salt Sensitivity of Blood Pressure, High Blood Pressure
Not yet recruiting
Beta-2 Adrenergic Receptor Polymorphic Variants: An Endotype of Salt Sensitive Hypertension (Beta2AR).
Genetics in Hypertension
Not yet recruiting
Gut Microbiome, Metabolome, and SSBP
Salt-sensitivity of Blood Pressure
Recruiting
Salt Sensitivity Evaluation Via N-of-1 Trials (SENSE-Salt)
Salt-Sensitivity of Blood Pressure, Hypertension
RecruitingPhase 4
Forebrain Electroneutral Transporters in Salt-sensitive Hypertension: an MRI Study
Salt-Sensitivity of Blood Pressure

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

The record lists no contact. Use the official record to reach the sponsor.

2 sites in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A study testing High Salt Diet and Low Salt Diet in people with Salt Sensitivity of Blood Pressure and Hypertension, run by Vanderbilt University Medical Center at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 7 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 7 Jul 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Salt Sensitivity of Blood Pressure (time frame: 14 days total which is 7 days each of high- and low-salt diet). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04258332, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jul 2026.